AI-rendered 3D representation of an activated dendritic cell with a coral-colored nucleus, highlighting the use of the new reporter model. The nucleus of the cells of interest has been labeled scarlet.
Image Credit: Courtesy of University of Manchester
Scientific Frontline: Extended "At a Glance" Summary: Activated Dendritic Cells
The Core Concept: Activated dendritic cells are a specialized population of immune cells that orchestrate and sustain the body's natural defense mechanisms against cancer.
Key Distinction/Mechanism: Rather than merely launching an initial anti-tumor immune response, these cells are essential for efficiently activating cancer-killing T cells and maintaining their functional strength once they are inside the tumor.
Major Frameworks/Components:
- Novel Mouse Models: The development of the first animal models capable of selectively labeling or removing activated dendritic cells to observe their exact immunological functions.
- T Cell Activation: The biological mechanism by which dendritic cells successfully prime, deploy, and support cancer-killing T cells.
- Intratumoral Sustenance: The critical, ongoing support provided by dendritic cells within the tumor microenvironment, which prevents the exhaustion of attacking immune cells.
Branch of Science: Immunology, Oncology, and Cellular Biology.
Future Application: Enhancing the effectiveness of current cancer immunotherapies, overcoming treatment resistance, and accelerating related research into infectious and autoimmune diseases.
Why It Matters: Because many patients currently do not respond to modern immunotherapies, finding methods to therapeutically boost activated dendritic cells could transform cancer treatment and save lives by strengthening coordinated immune responses.
A little-known group of hard-to-find immune cells could help transform cancer treatment, scientists at the University of Manchester’s Cancer Research UK Manchester Institute have found.
Their discovery, published in the world-leading journal Immunity on August 4, 2026, centers on activated dendritic cells, a specialized population of immune cells that orchestrate the body’s attack on cancer.
To make the discovery, the researchers developed the first mouse models capable of specifically labeling or removing activated dendritic cells.
This allowed them to determine exactly how activated dendritic cells contribute to anticancer immunity.
The models are expected to accelerate research into activated dendritic cells across cancer, infections, and autoimmune diseases.
Until now, scientists have struggled to understand precisely how activated dendritic cells contribute to anticancer immunity because suitable models did not exist.
Using the new models, the team showed that activated dendritic cells are indispensable for effective anticancer immune responses.
Without them, cancer-killing T cells could neither be efficiently activated nor maintain their strength once inside tumors.
As a result, both spontaneous immune control of cancer and the efficacy of immunotherapy were impaired.
First author Dr. Maria Koufaki said, “Modern immunotherapies rely on strong and coordinated immune responses, yet many people still do not benefit from these treatments. If we can find ways to boost activated dendritic cells, we may be able to strengthen the immune system’s response to cancer and help more patients benefit from immunotherapy, including some whose cancers currently resist treatment.”
Senior author Professor Santiago Zelenay said, “Activated dendritic cells do not just launch the antitumor immune responses; they are also essential for sustaining them within the tumor itself. This changes how we think about their role and opens up new opportunities to improve cancer immunotherapy.”
Research information manager at Cancer Research UK, Dr. Marianne Baker, said, “Immunotherapies that harness our immune system to beat cancer are saving lives, but we don't yet understand why they work for some people and not others. The models developed as part of this study could help scientists unlock ways to boost these revolutionary treatments via dendritic cells, a type of immune cell. We need more research to get there, but this work could help to solve unanswered questions in cancer immunotherapy and beyond.”
Funding: The work was funded by Cancer Research UK, with additional support from the European Molecular Biology Organization and the Italian Association for Cancer Research UK.
Published in journal: Immunity
Authors: Maria A. Koufaki, Erin Richardson, Eduardo Bonavita, Richard Reeves, Agrin Moeini, Shih-Chieh Chiang, Antonia Banyard, Massimo Russo, Charles H. Earnshaw, Charlotte R. Bell, Eimear Flanagan, Victoria S. Pelly, Laetitia Nebot-Bral, Anna Pidoux, Poppy Dunn, Sudhakar Sahoo, Sandrine Henri, Bernard Malissen, Andrew S. MacDonald, Natalia Moncaut, and Santiago Zelenay
Source/Credit: University of Manchester
Edited by: Scientific Frontline
Reference Number: imgy080426_01